Investment Trends in Early Stage BioPharma Report

The US Market and LBP Development

US companies have long been at the forefront of Microbiome drug development, thanks to robust support from academic research and substantial funding from the National Institutes of Health (NIH). Coupled with this, is the prominence of Live Biotherapeutic Products (LBP), which have consistently been the leading therapeutic class for Microbiome drug developers.

LBP Development in the US Market Report

This report covers:

A detailed US geographic overview, including breakdowns by company type and headquarters location
Analysis of US funding trends since 2023, categorized by type, deal value, and therapeutic class
Comparative analysis of LBPs in clinical trials since 2014, alongside WEDPs
Comprehensive overview of therapeutic classes for LBPs

Download Report

You May Also Be Interested In…

Microbiome Landscape Review

Access Review

Microbiome Drug Development in Asia

Access Infographic

Webinar date:

Microbiome Targeting Therapeutics in Infectious Disease

Access Webinar

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more